Medical Advocates
Atazanavir (Reyataz)

Conference Citations

19th CROI
18th CROI
XVIII International AIDS Conference
17th CROI
5th IAS Conference
16th CROI
Ninth Int. Congress on Drug Therapy in HIV Infection
XVII International AIDS Conference
15th CROI
4th IAS Conference
14th CROI
Conference Archives

Atazanavir Main Page

Main New/Newsworthy

Home Page

Last updated: March 10, 2012
Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader

19th CROI

POSTER
A Comparison of the Pharmacokinetics of Darunavir, Atazanavir, and Ritonavir during Pregnancy and Post-partum
A Colbers, J Molto, J Ivanovic, et al
PDF Poster Abstract

POSTER
Pharmacokinetic Interaction between the HCV Protease Inhibitor Boceprevir and Ritonavir-boosted HIV-1 Protease Inhibitors Atazanavir, Lopinavir, and Darunavir
E Hulskotte, H-P Feng, F Xuan, et al
PDF Poster Abstract
POSTER
Premature Discontinuation of Atazanavir/ritonavir and UGT1A1 Variants: ACTG Protocol A5202
H Ribaudo, E Daar, C Tierne, et al
PDF Poster Abstract
Effect of Sex and NRTI on Atazanavir Pharmacokinetics: ACTG Study A5202
C Venuto, Q Ma, K Mollan, et al
Abstract

6th IAS Conference on HIV Pathogenesis, Treatment
and Prevention

POSTER
Methods for reducing the costs of antiretroviral treatments (ART) without reducing effectiveness
R.M. Grimes, T.A. Shenouda
Poster Abstract

POSTER
Factors associated with a good HAART response in HIV patients
D. Perez, J. Perez
Poster Abstract

POSTER
Late HAART initiation in Latin America and the Caribbean: late testers and late presenters
B. Crabtree-Ramírez, Y. Caro-Vega, B. Shepherd, et al
Poster Abstract

POSTER
Factors associated with HAART adherence in adolescents and youth living with HIV in Argentina
M.V. Zalazar, M. Vazquez, M. Rojo, et al
Poster Abstract
Cumulative viremia under HAART predicts long-term clinical outcomes
V.D. Lima, J. Sierra-Madero, Z. Wu, et al
Abstract
Characterizing nonadherence among urban HIV-infected adolescents
R. Lagrange, M. Lewis, A. Vyas, et al
Abstract
The problematic of adolescent antiretroviral treatment adherence
Z.-K. Alice, K. Sonia, C. Bernadette
Bridging the gap of poor adherence of adolescent on antiretroviral drugs (ARVS) in Baylor College of Medicine
Children´s Foundation, Uganda
J. Paalo, L. Opendi, S. Okoboi, et al
Abstract
Cumulative viremia under HAART predicts long-term clinical outcomes
V.D. Lima, J. Sierra-Madero, Z. Wu, et al

Is the magic bullet already too late: a systematic review of the prevalence of transmitted HIV drug
resistance in treatment-naïve patients, South Africa
K. Velen, J. Klausner
Abstract

Long term follow-up of antiretroviral therapy for HIV-2 infection in Senegal, West Africa
S.N. Ba, N.M. Dia Badiane, M. Toure. et al
Abstract

18th CROI

A WEEK-IN-REVIEW FEATURED REPORT
POSTER
Changes in Lymphocyte Populations and Immune Activation during Regimen Simplification to ATV/RTV Alone as HIV-1
Maintenance Therapy (ACTG 5201)
PDF Poster Abstract

POSTER
Intracellular Pharmacokinetics of ATV/RTV Is Influenced by Solute Carrier Organic Anion Transporter 3A1 Expression
M Siccardi, A D’Avolio, L Baietto, et al
PDF Poster Abstract

POSTER
Randomized Comparison of DRV/r vs ATV/r on Serum Lipids in HIV⁺ Persons on Fully Suppressive LPV/r or FPV/r with
High Serum Triglycerides
D Skiest, C Cohen, H Khanlou, et al
PDF Poster Abstract

POSTER
Sex- and Geographic-based Differences in ATV Pharmacokinetics in Subjects Treated with ddI-EC, FTC, and ATV
in the ACTG PEARLS Study
A Andrade, G Baheti, L Smeaton, et al
PDF Poster Abstract
Pharmacokinetics of DRV/r and ATV/r Once Daily over 72 Hours following Drug Cessation
M Boffito, A Jackson, A Amara, et al
Abstract
Population Pharmacokinetics of ATV/r in HIV-1⁺ Children and Adolescents
F Foissac S Blanche, C Dollfus, et al
Abstract
Small but Significant and Non-progressive Decline in GFR Observed in Therapy-naïve HIV⁺ Subjects Commencing r/ATV,
Compared to either EFV or ZDV/ABC with TDF/FTC after 48 Weeks: A Randomized Controlled Study
C Dazo, P Fahey, R Puls et al
Abstract

XVIII International AIDS Conference

POSTER
Virological response to atazanavir, ritonavir and tenofovir/emtricitabine: relation to individual
pharmacokinetic parameters and adherence measured by medication events monitoring system
(MEMS) in naïve HIV-infected patients (ANRS134 trial)
C. Goujard, A. Barrail-Tran, X. Duval, et al
PDF Poster Abstract

POSTER
METABOLIK (Metabolic Evaluation in Treatment-naïves Assessing the impact of two BOosted
protease inhibitors on LIpids and other marKers): comparison of the metabolic effects of
darunavir/ritonavir versus atazanavir/ritonavir over 12 weeks
J. Aberg, T. Overton, S. Gupta, et al
PDF Poster Abstract

POSTER
Long-term efficacy and safety of a switch to unboosted atazanavir (ATV) in well controlled HIV-1
infected patients, results of the NEAT Unboosted Atazanavir Cohort
A. Rachline, C. Torti, J. Medrano, et al
PDF Poster Abstract
Safety and efficacy of treatment simplification to atazanavir/ritonavir plus lamivudine in patients on
two NRTIs plus atazanavir/ritonavir with optimal virologic control: 24 weeks results from a pilot study
(atazanavir and lamivudine simplification study, ATLAS)
A. De Luca, L. Bracciale, M. Doino, et al
Abstract
Therapeutic drug monitoring (TDM) of different doses of atazanavir (ATV)/ ritonavir (RTV) when
co-administered with the non-nucleoside reverse transcriptase inhibitors (NNRTIs) efavirenz or
nevirapine
J. Toy, C. Olatunbosun, M. Harris, et al
Abstract

17th CROI

POSTER
Identification of Novel Factors that Influence Atazanavir Exposure in a Diverse
Population of HIV-infected Women under Conditions of Actual Use
M Gandhi, S Gange, C Ponath, et al
PDF Poster Abstract

POSTER
Steady State Pharmacokinetic of Ritonavir-boosted Atazanavir in 31 Pregnant Women before
and after Delivery.
D Ripamonti, D Cattaneo A d’Avolio, et al
PDF Poster Abstract

POSTER
Effect of Atazanavir and Atazanavir/Ritonavir on the Pharmacokinetics of the Next Generation
Integrase Inhibitor, S/GSK1349572
I Song, J Borland, S Chen, et al
PDF Poster Abstract

A Population Pharmacokinetic Model Illustrates an Association Between a Pregnane-X-Receptor
(PXR) Polymorphism and Boosted Atazanavir Clearance
A Schipani, M Siccard, M Boffito, et al

5th IAS Conference on HIV Pathogenesis, Treatment
and Prevention

CONFERENCE POSTER
The safety, efficacy, and steady state pharmacokinetics of atazanavir/ritonavir (ATV/r) once daily
given in combination with twice daily AZT/3TC during pregnancy: results of study AI424182
F. Conradie, C. Zorilla, D. Josipovic, et al
PDF Poster Abstract
CONFERENCE POSTER
Long-term efficacy and safety of a switch to unboosted atazanavir-based regimens among HIV-infected
patients with suppression of viral replication: a retrospective cohort study
J. Pavie, A. Rachline, R. Porcher, et al
PDF Poster Abstract
CONFERENCE POSTER
Phenotypic susceptibility and drug resistance profile of HIV-1 B, C and AG clones selected with
atazanavir, lopinavir and nelfinavir
I. Lisovsky, J.L. Martinez Cajas, M. Oliveira
PDF Poster Abstract
Efficacy and safety of atazanavir/r vs. lopinavir/r in treatment-naïve patients with advanced disease:
CASTLE study 96-week results
J. Uy, R. Yang, V. Wirtz, et al
Abstract
Efficacy, safety and pharmacokinetic profile of a simple antiretroviral regimen containing unboosted
atazanavir, didanosine EC and lamivudine in naïve HIV-1 infected patients in Senegal (REYADAK
study-IMEA-031)
R. Landman, M.-B. Diallo, G. Peytavin, et al
Abstract
Efficacy, safety and pharmacokinetic profile of a simple antiretroviral regimen containing unboosted
atazanavir, didanosine EC and lamivudine in naïve HIV-1 infected patients in Senegal (REYADAK
study-IMEA-031)
R. Landman, M.-B. Diallo, G. Peytavin, et al
Abstract
Similar efficacy and tolerability of atazanavir (ATV) compared to ATV/ritonavir (RTV, r), each
in combination with abacavir/lamivudine (ABC/3TC), after initial supression with ABC/3TC +
ATV/r in HIV-1 infected patients: 84 week results of the ARIES trial
K. Squires, B. Young, E. DeJesus, et a
Abstract
A short trial of unboosted atazanavir in patients with high trough levels on ritonavir-boosted
atazanavir to select candidates for unboosted maintenance therapy
S. Guillemi, J. Toy, M. Harris, et al
Abstract

16th CROI

CPOSTER
Endothelial Function, Lipoproteins, and Cardiovascular Inflammatory Markers in Treated HIV-infected Patients
with Hyperlipidemia Who Were Switched to an Atazanavir-containing Regimen or Continued on Other Protease
Inhibitor-based Therapy: Switch to Atazanavir and Brachial Artery Reactivity Study
R Murphy, C Zala, B Berzins, et al
PDF Poster Abstract
POSTER
Atazanavir Pharmacokinetics with and without Tenofovir during Pregnancy
M Mirochnick, A Stek, E Capparelli, et al
PDF Poster Abstract
Pharmacokinetics and Safety of Twice-daily Atazanavir (300 mg) and Raltegravir (400 mg) in Healthy Subjects
L Zhu, L Mahnke, J Butterton, et al
Abstract

Ninth International Congress on Drug Therapy in HIV Infection

Efficacy and safety of 48-week maintenance with QD ATV vs ATV/r (both + 2NRTIs) in patients with
VL <50 c/mL after induction with ATV/r + 2NRTIs: study AI424136
JF Delfraissy, S Moreno, J Sanz-Moreno,et al
PDF Abstract

Efficacy and safety by baseline HIV-RNA and CD4 count in treatment-naive patients treated with atazanavir/r
and lopinavir/r in the CASTLE study
Uy J, Yang R, Thiry A, Absalon J, et al
Abstract

L76V – clinically relevant resensitization of the protease inhibitors (PIs) saquinavir (SQV) and atazanavir (ATV)
Vachta J, Wiesmann F, Braun P, et al
Abstract

Protease inhibitor atazanavir induces leukocyte-endothelial cell interactions in the microvasculature
Andrade MM, De Pablo-Bernal C, Esplugues JV, et al
Abstract

Efficacy and safety of switching from lopinavir/r to atazanavir/r in suppressed patients receiving a LPV/r-containing
HAART: ATAZIP 96-week results
Mallolas J, Podzamczer D, Domingo P, et al
Abstract

Atazanavir is safe and efficacious in HBV and HCV co-infected patients: results of AI424138 (CASTLE)
Absalon J, Thal G, Thiry A, Yang R, et al
Abstract

Impact of age on pharmacokinetics of boosted atazanavir 300/100 in Thai HIV-infected patients
Avihingsanon A, van der Lugt J, Kerr S, et al
Abstract

Atazanavir (ATV) plasma concentrations at different times after drug uptake: associations with virologic response
and hyperbilirubinemia
Fabbiani M, Di Giambenedetto S, Ragazzoni E, et al
Abstract

Improvement of atazanavir-induced hyperbilirubinaemia following TDM-guided atazanavir dose reduction
Giola M, Cusato M, Villani P, et al
Abstract

XVII International AIDS Conference

Necessity of intensive UV-phototherapy for atazanavir associated neonatal hyperbilirubinemia: a case report
C. Ferreira, G. Morau, G. Peytavin, et al
Abstract
Fasting increases serum bilirubin concentrations in patients on atazanavir
G. Lopardo , L. Espinola , E. Bissio, et al
Abstract
Pharmacokinetic drug-drug interaction between IDX899 and Atazanavir
X.-J. Zhou , K. Pietropaolo, B. Belanger, et al
Abstract
Long term surveillance of severe adverse events in HIV-1 infected patients treated with atazanavir: results from the
SCOLTA project
R. Giuntini, C. Martinelli, E. Ricci, et al
Abstract
Increase in bilirubin in HIV/HCV coinfected patients treated with atazanavir following initiation of peginterferon plus
ribavirin
S. Rodriguez-Novoa, J. Morello, M. Gonzalez, et al
Abstract
Effect of simplification from protease inhibitors (PIs) to boosted atazanavir (ATV/r)-based regimens in real-life conditions:
final 1 year results of GESIDA 44/04 SIMPATAZ study
R. Rubio, J. Carmen, V. Asensi, et al
Abstract
Efficiency, safety and plasma concentrations of atazanavir, ritonavir and nevirapine in HIV-1 infected patients receiving
ATV/r + NVP once daily regimen
M. Kirstette, O. Taulera, M. Bary, et al
Abstract
Resistance to unboosted atazanavir among HIV-1 subtype A/E infected patients who are naïve to protease inhibitor
S. Sungkanuparph, W. Manosuth, S. Wiboonchutikul, et al
Efficacy and safety by racial group in ARV-naive subjects treated with atazanavir/ritonavir or lopinavir/ritonavir:
48 week results for the CASTLE study (AI424138)
D. McGrath, J. Uy, R. Yang, et al
Abstract
Pharmacokinetics and clinical outcomes with Atazanavir 300 mg QD/ritonavir 100 mg (ATV/r) QD + ZDV/3TC
during the 3rd trimester of pregnancy in HIV+ women: interim results from BMS AI424182
T. Eley, E. Vandeloise, M. Child, et al
Abstract
The effects of aging on Atazanavir plasma concentrations in HIV-infected patients treated with ATV/r (300/100 mg qd)
containing regimen
A. Rahal, D. Descamps D. Manene, et al
Abstract
Impact of baseline resistance on virologic efficacy of dual-boosted once-daily (QD) atazanavir, fosamprenavir, and
ritonavir (ATV/FPV/RTV)
U.F. Bredeek, B. Williams, R. Feldman, T. Lancaster
Abstract
Health related quality of life (HRQoL) improvement in antiretroviral (ARV) naïve HIV-infected patients on ritonavir with
atazanavir or lopinavir regimens: week 24 results from AI424138
J. Su, J. Absalon, M. Mancini, et al
Abstract
Necessity of intensive UV-phototherapy for atazanavir associated neonatal hyperbilirubinemia: a case report
C. Ferreira, G. Morau, G. Peytavin, et al
Abstract

15th CROI

NEWS RELEASE
CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ®
(atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks
in Previously Untreated HIV-Infected Adult Patients
BMS February 06, 2008

Efficacy and Safety of Once-daily Atazanavir/Ritonavir Compared to Twice-daily Lopinavir/Ritonavir,
Each in Combination with Tenofovir and Emtricitabine in ARV-naive HIV-1-infected Subjects:
The CASTLE Study, 48-week Results
J-M Molina, J A Villanueva, J Echevarria, et al
Abstract
POSTER
Switch from Ritonavir-boosted to Unboosted Atazanavir Guided by Monitoring Atazanavir
Concentrations in a Clinical Setting
SRodriguez-Novoa, J Morello
PDF Poster Abstract

POSTER
Treatment Responses to Atazanavir-containing HAART in a Drug-naïve Pediatric Population
in South Africa
T Meyers R Rutstein, P Samson,
PDF Poster Abstract

POSTER
Absence of Protease Resistance with Virologic Rebound by Single Genome Sequencing on
Atazanavir/Ritonavir as Simplified Maintenance Therapy: ACTG 5201
J McKinnon, T Wilkin, S Swindells, et al
PDF Poster Abstract

POSTER
Hepatic Transaminase Elevations and Gastrointestinal Intolerance when HIV-negative Healthy
Volunteers on Rifampin add Twice-daily Atazanavir ( 300 mg)/Ritonavir ( 100 mg): ACTG Protocol
A5213
D Haas, S Koletar, L Laughlin, et al
PDF Poster Abstract

POSTER
Rates of Ritonavir Non-adherence and Dose Staggering in HIV⁺ Patients Receiving RTV-boosted
Atazanavir or Fosamprenavir
J Shuter, R Rode, J Sarlo, B Zingman
PDF Poster Abstract

POSTER
Atazanavir in Pregnancy: Influence on Neonatal Hyperbilirubinemia
C Ferreira, C Floch-Tudal, F Meier, et al
PDF Poster Abstract

Steady State Pharmacokinetics and Safety of Atazanavir after Treatment with ATV 300 mg
Once Daily/Ritonavir 100 mg Once Daily + ZDV/3TC during the Third Trimester in HIV⁺ Women
T Eley, E Vandeloise, M Child
Abstract

4th IAS Conference on HIV Pathogenesis, Treatment
and Prevention

Efficacity, safety, and plasma concentration of a double boosted PI combination atazanavir
(ATV/fosamprenavir(FPV)/ritonavir(RTV) a once daily regimen in HIV-1 infected patients: the
TELAZ study
Kirstetter M, Peytavin G, Delaugerre C, et al
Abstract

Hepatic effects of atazanavir plus ritonavir (ATV/r)-based combinations in patients with
hepatitis virus coinfection: relationship with pre-existing liver damage
Abdel-Kader L, Santos J, Rivero A, et al
Abstract

Exploring the impact of therapeutic drug monitoring (TDM) in patients receiving atazanavir–
ritonavir (ATV/r) boosted regimens
Guillemi S, Harrigan R, Yip B, et al
Abstract

Efficacy and safety of switching from lopinavir/r (LPV/r) to atazanavir/r (ATV/r) in patients
with virologic suppression receiving a LPV/r containing HAART: the ATAZIP study
Mallolas J, Podzamczer D, Domingo P, et al
Abstract

Efficacy and safety of atazanavir-based therapy in antiretroviral naïve HIV-1 infected subjects,
both with and without ritonavir: 96-week results from AI424089
Malan N, Krantz E, David N, et al
Abstract

Once-daily double-boosted protease inhibitor regimen of atazanavir, saquinavir, and ritonavir:
60-week efficacy and metabolic effects
Manosuthi W, Chaovavanich A, Prasithsirikul W, et al
Abstract

Treatment simplification to an atazanavir-containing regimen: impact on patient´s perception of
adverse events severity
Gatell JM, L'Italien G, Wirtz V, et al
Abstract

Metabolic results in the Simplification Lopinavir to Atazanavir Trial (SLOAT)
Ramírez-Olivencia G, Ruiz-Sancho A, Martín-Carbonero L, et al
Abstract

Pharmacokinetics of atazanavir in HIV-1-HCV co-infected patients
Gatti F, Nasta P, Matti A, et al
Abstract

HIV-1 protease mutation L76V enhances susceptibility to atazanavir and saquinavir in multidrug-
resistant HIV-1 infected patients
Braun P, Wiesmann F, Walter H, et al
Abstract

Efficacy and safety of atazanavir in HIV-infected patients with liver cirrhosis
Hermida Donate JM, Quereda C, Moreno A, et al
Abstract

Efficacy and safety of non-boosted to ritonavir-boosted atazanavir among antiretroviral naïve
patients
Horberg M, Klein D, Hurley L, et al
Abstract

14th CROI

Assessment of Pharmacokinetic/Pharmacodynamic Relationships through 48 Weeks from a Study
in HIV⁺, ART-naive Subjects Receiving Antiretroviral Regimens Containing Atazanavir 400 mg or
Atazanavir/Ritonavir 300/100 mg Once Daily
R Bertz, Y Wang, L Mahnke, et al
Abstract
The PACTG 1020A Protocol: Atazanavir with or without Ritonavir in HIV-infected Infants, Children,
and Adolescents
R Rutstein, P Samson, J Kiser, et al
Abstract
Effect of Rifampin on Pharmacokinetics and Safety of Twice-daily Atazanavir: ACTG Protocol A5213
E Acosta, M Kendall, J Gerber, et al
Abstract
Effect of Famotidine 20- and 40-mg Dosing Regimens on the Bioavailability of Atazanavir with Ritonavir
in Combination with Tenofovir in Healthy Subjects
S Agarwala, A Persson, T Eley, et al
Abstract
Atazanavir Use in Pregnancy: A Report of 33 Cases
M Natha, P Hay, G Taylor, et al
Abstract
Effects of Atazanavir or Saquinavir Once Daily with Ritonavir 100 mg and Tenofovir/Emtricitabine as
Initial Therapy for HIV-1 Infection on Peripheral Glucose Disposal: A Randomized Open-label Study
A Jackson, N Patel, G Lo, et al
Abstract

POSTER
Phenotypic Susceptibility in vitro to Amprenavir, Atazanavir, Darunavir, Lopinavir, and Tipranavir of
HIV-2 Clinical Isolates from the French ANRS HIV-2 Cohort
D Desbois, G Peytavin, S Matheron, et al
PDF Poster     Abstract

POSTER
Atazanavir-based HAART in Pregnancy
D Ripamonti, D Cattaneo, M Airoldi, et al
PDF Poster     Abstract
POSTER
Body Composition Changes in ART-naive Subjects Treated with Atazanavir or Atazanavir/Ritonavir-
based Once-daily HAART: 48-Week Computed Tomography and DEXA Data
D McGrath, D Frederick, V Wirtz, et al
PDF Poster     Abstract

POSTER
Gilbert’s Disease and Atazanavir: From Phenotype to UDP-glucuronosyltransferease Haplotype
T Lankisch, G Behrens, U Moebius, et al
PDF Poster    Abstract

Atazanavir Main Page

Main New/Newsworthy

Home Page